Ascentage Pharma Group International (AAPG) Receivables (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Receivables for 3 consecutive years, with $35.9 million the latest figure, recorded in Q4 2025.

• Quarterly Receivables rose 188.58% year-over-year to $35.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.9 million (up 188.58% YoY) and the FY2025 annual result came in at $35.4 million, up 184.81% from the prior year.
• Receivables grew to $35.9 million in Q4 2025 per AAPG's latest filing, from $10.9 million in the prior quarter.
• Over the last five years, Receivables for AAPG reached as high as $35.9 million in Q4 2025 and fell as low as $10.9 million in Q2 2025.
• A 3-year average of $20.1 million and a median of $16.8 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables slumped 41.33% — and 2025, when it surged 188.58%.
• Year by year, Receivables stood at $21.2 million in 2023, then sank by 41.33% to $12.4 million in 2024, then surged by 188.58% to $35.9 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $35.9 million, $10.9 million, and $12.4 million for Q4 2025, Q2 2025, and Q4 2024 respectively.